Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Vicore Pharma Holding AB ( (SE:VICO) ).
Vicore Pharma Holding AB announced its participation in two major healthcare conferences in the USA, where the company’s CEO and VP of IR will present and engage in meetings. This participation highlights Vicore’s strategic efforts to engage with investors and stakeholders, potentially enhancing its visibility and positioning in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), for treating respiratory and fibrotic diseases like idiopathic pulmonary fibrosis (IPF). Their leading drug candidate, buloxibutid, is in a Phase 2b trial and has received Orphan Drug and Fast Track designations from the FDA.
Average Trading Volume: 776,787
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.55B
See more insights into VICO stock on TipRanks’ Stock Analysis page.